QP Wealth Management LLC Buys New Position in Astrazeneca Plc $AZN

QP Wealth Management LLC purchased a new stake in Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 8,816 shares of the company’s stock, valued at approximately $810,000.

Several other institutional investors have also added to or reduced their stakes in AZN. Triumph Capital Management purchased a new position in shares of Astrazeneca in the 3rd quarter valued at approximately $25,000. Rakuten Investment Management Inc. purchased a new stake in Astrazeneca during the 3rd quarter worth approximately $31,000. JPL Wealth Management LLC purchased a new stake in Astrazeneca during the 3rd quarter worth approximately $35,000. E Fund Management Hong Kong Co. Ltd. increased its stake in Astrazeneca by 144.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after purchasing an additional 275 shares in the last quarter. Finally, Abound Wealth Management raised its holdings in shares of Astrazeneca by 1,767.9% in the third quarter. Abound Wealth Management now owns 523 shares of the company’s stock worth $40,000 after buying an additional 495 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the subject of several research reports. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday. HSBC reissued a “buy” rating and issued a $108.00 target price on shares of Astrazeneca in a research report on Wednesday, December 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $103.00 price target on shares of Astrazeneca in a research report on Wednesday, December 3rd. Barclays reiterated an “overweight” rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

Astrazeneca Trading Down 2.9%

NYSE:AZN opened at $183.40 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a 1-year low of $122.48 and a 1-year high of $212.71. The firm has a market capitalization of $284.44 billion, a PE ratio of 28.00, a price-to-earnings-growth ratio of 1.42 and a beta of 0.32.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be given a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is currently 66.26%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.